CAN-FITE BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.8 ILa | 0.00% |
|
+3.70% | +7.69% |
| May. 12 | Transcript : Can-Fite BioPharma Ltd. - Special Call | |
| May. 09 | Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study | CI |
| Sales 2024 * | 900K 330M | Sales 2025 * | 900K 330M | Capitalization | 11.41M 4.19B |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -2.57B | Net income 2025 * | -8M -2.94B | EV / Sales 2024 * | 12.7 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 12.7 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Can-Fite BioPharma Ltd.
More press releases
| 1 week | +7.69% | ||
| Current month | +7.69% | ||
| 1 month | +7.69% | ||
| 3 months | +7.69% | ||
| 6 months | +3.70% | ||
| Current year | +7.69% |
1 week
2.80
3.00
1 month
2.603.00
Current year
2.503.00
1 year
2.504.10
3 years
2.1031.10
5 years
2.1052.80
10 years
2.101 163.00
| Managers | Title | Age | Since |
|---|---|---|---|
Motti Farbstein
CEO | Chief Executive Officer | 59 | 03-07-31 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Abraham Sartani
BRD | Director/Board Member | 76 | 00-12-31 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 2.8 | 0.00% | 708 096 |
| 24-05-22 | 2.8 | -3.45% | 2,950,191 |
| 24-05-21 | 2.9 | 0.00% | 1,960,647 |
| 24-05-20 | 2.9 | 0.00% | 8,177,351 |
| 24-05-19 | 2.9 | +11.54% | 7,665,227 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 23, 2024 at 10:24 am EDT
More quotes
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.028
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.69% | 11.41M | |
| -1.62% | 89.22B | |
| +2.24% | 40.49B | |
| -15.15% | 32.79B | |
| +64.13% | 26.23B | |
| -21.78% | 14.52B | |
| -7.69% | 13.09B | |
| -42.60% | 11.6B | |
| -12.64% | 11.5B | |
| +4.94% | 8.82B |
- Stock Market
- Equities
- CANF Stock
